230 related articles for article (PubMed ID: 6217579)
1. A kinetic method for characterization of heterogenous fibrinogen and its application to fibrinogen Grand Rapids, a congenital dysfibrinogenemia.
Higgins DL; Lewis SD; Penner JA; Shafer JA
Thromb Haemost; 1982 Oct; 48(2):182-6. PubMed ID: 6217579
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen Aarhus--a new case of dysfibrinogenemia.
Hessel B; Stenbjerg S; Dyr J; Kudryk B; Therkildsen L; Blombäck B
Thromb Res; 1986 Apr; 42(1):21-37. PubMed ID: 2939591
[TBL] [Abstract][Full Text] [Related]
3. A new dysfibrinogenemia: fibrinogen Oslo IV.
Stormorken H; Brosstad F; Seim H
Thromb Haemost; 1983 Apr; 49(2):120-2. PubMed ID: 6868008
[TBL] [Abstract][Full Text] [Related]
4. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules.
Jandrot-Perrus M; Aurousseau MH; Rabiet MJ; Josso F
Thromb Res; 1982 Sep; 27(6):659-70. PubMed ID: 6217586
[TBL] [Abstract][Full Text] [Related]
5. [Fibrinogen Bern II: hereditary fibrinogen variant with amino acid substitution of arginine replaced by histidine in position 16 of the A alpha chain].
Rupp C; Sievi R; Furlan M; Beck EA
Schweiz Med Wochenschr; 1983 Oct; 113(40):1460-2. PubMed ID: 6648427
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation.
Rodeghiero F; Castaman GC; Dal Belin Peruffo A; Dini E; Galletti A; Barone E; Gastaldi G
Thromb Haemost; 1987 Jun; 57(3):252-8. PubMed ID: 2958952
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA.
Engesser L; Koopman J; de Munk G; Haverkate F; Nováková I; Verheijen JH; Briët E; Brommer EJ
Thromb Haemost; 1988 Aug; 60(1):113-20. PubMed ID: 3142089
[TBL] [Abstract][Full Text] [Related]
9. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
Ebert RF; Schreiler WE; Bell WR
Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginine leads to histidine substitution.
Southan C; Kehl M; Henschen A; Lane DA
Br J Haematol; 1983 May; 54(1):143-51. PubMed ID: 6849832
[TBL] [Abstract][Full Text] [Related]
11. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen Kiel: a congenital dysfibrinogenaemia with (A alpha-16 Arg----His) substitution characterized by HPLC without prior isolation of fibrinogen.
Seydewitz HH; Gram J; Bruhn HD; Witt I
Blood Coagul Fibrinolysis; 1991 Aug; 2(4):501-6. PubMed ID: 1768762
[TBL] [Abstract][Full Text] [Related]
13. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
Vila V; Regañón E; Aznar J; Navarro G; Salas M
Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
[TBL] [Abstract][Full Text] [Related]
17. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].
Furlan M; Leupin L; Biasiutti FD; Lämmle B
Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen and dysfibrinogenemia.
Morse EE
Ann Clin Lab Sci; 1980; 10(4):351-5. PubMed ID: 7447388
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
Siebenlist KR; Prchal JT; Mosesson MW
Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
